2 recruiting, 1 active not recruiting, 1 unknown. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Recruiting 2, Active not recruiting 1, Unknown 1 |
Follow inebilizumab: new trials by email Literature Review of inebilizumab trials Research Report on inebilizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD Rituximab (R), Eculizumab (Soliris®), Ravulizumab - NMOSD | Phase 4 | Recruiting | Massachusetts General Hospital | 540 | 2026-09-01 | 2026-09-24 |
| Inebilizumab for the Treatment of Patients With Type 1 Autoimmune Pancreatitis Inebilizumab - Type 1 AIP | Phase 4 | Recruiting | Ruijin Hospital | 50 | 2025-10-01 | 2026-10-07 |
| Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Blood tests, Inebilizumab - Neuromyelitis Optica Spectrum Disorder | Phase 4 | Active not recruiting | Amgen | 32 | 2024-04-02 | 2025-11-21 |
| A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Inebilizumab - Neuromyelitis Optica Spectrum Disorders | Phase 4 | Unknown | Hansoh BioMedical R&D Company | 33 | 2024-02-25 | 2024-01-18 |
Neuromyelitis Optica (2) · Autoimmune Pancreatitis (1)
Amgen (1) · Hansoh BioMedical R&D Company (1) · Massachusetts General Hospital (1) · Ruijin Hospital (1)
China (3) · United States (2) · Czechia (1) · Germany (1) · Hungary (1) · Poland (1) · South Korea (1) · Thailand (1)